Tradestie Institutional Equity Comparison Engine

ENTX vs PTN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ENTX Overall Edge

ENTX Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PTN counters with relative strength in Valuation. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus PTN at 42.9x Forward P/E and -65.7% operating margin (-80.1% YoY). In options structure, ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro) against PTN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PTN
ENTX N/M vs PTN 42.9x Fwd P/E
Growth & Margin Winner ENTX
Op Margin 0.0% vs -65.7% ยท YoY -100.0% vs -80.1%
Momentum & Technical Winner ENTX
1Y +10.2% vs -43.3% ยท 52W Pos 64% vs 6%
Options & Structure Winner ENTX
CONSOLIDATION (32nd %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap $541.6M
1M Return +12.69%
1Y Return +10.22%
Forward P/E N/M
Unified AI Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
1M Return +1.74%
1Y Return -43.29%
Forward P/E 42.9x
Unified AI Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENTX +10.22% PTN -43.29% Spread: +53.51 pp (ENTX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ENTX Revenue PTN Revenue ENTX Op. Margin PTN Op. Margin Margin Edge
FY2019 N/A $60M N/A 59.3% PTN
FY2020 $0M $0M -3059.7% -20007.6% ENTX
FY2021 $0M N/A -2139.6% N/A ENTX
FY2022 $0M $0M -9714.2% -2491.6% PTN
FY2023 N/A $0M N/A -668.7% PTN
FY2024 $0M $0M -5295.6% -501.0% PTN
FY2025 $0M N/A -27450.0% N/A ENTX
FY2026 N/A $10M N/A -65.7% PTN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENTX (7) vs PTN (3)
Institutional Metric ENTX PTN Criterion Row Winner
Market Capitalization Scale $541.6M $11.1M Larger Scale ENTX
Trailing P/E Ratio Valuation N/M 42.9x Lower Multiple PTN
Forward P/E Ratio Valuation N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY) Growth -100.0% -80.1% Higher Growth PTN
Operating Margin (TTM) Profitability 0.0% -65.7% Higher Margin ENTX
Net Profit Margin Profitability 0.0% -63.5% Higher Margin ENTX
Return on Equity (ROE) Capital Efficiency -20.3% -877.5% Higher ROE ENTX
52-Week Range Position Momentum 64% ($1โ€“$4) 6% ($5โ€“$31) Stronger Trend ENTX
Beta / 30D Volatility Risk Regime 1.07ฮฒ ยท 46% Vol 0.87ฮฒ ยท 106% Vol Lower Realized Risk ENTX
Unified Institutional Score Composite Signal 53.5 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite ENTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENTX vs PTN Buy Guide
ENTX CONSOLIDATION
79d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 32nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PTN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENTX nor PTN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.